Pericarditis after therapy with interferon-α for chronic hepatitis C

Clinical Rheumatology

Volumn 18, Issue 2, 1999, Pages 177-179

  Boonen, Annelies ^a   Stockbrugger R W ^b   Van Der Linden, Sj ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Autoimmune diseases; Hepatitis C; Interferon alpha; Pericarditis

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; LABORATORY TEST; PERICARDITIS; PRIORITY JOURNAL; SERODIAGNOSIS; TREATMENT OUTCOME;

ADULT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PERICARDITIS;

EID: 0344780742     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670050081     Document Type: Article

References (39)

1. Pawlotsky JM, Roudot-Thoreval F, Simmonds P, Mellor J, Ben Yahia M, Andre C, et al. Extrahepatic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995;122:169-73.
2. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-5.
3. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatits C virus infection. N Engl J Med 1993;328:465-70.
4. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoreval F, et al. Immunologic disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8.
5. McMurray R, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997;26:689-701.
6. Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992;339:321-3.
7. Silva M, Li X, Cheinquer H, Kolodny L, Radick J, La Rue S, et al. HCV associated thrombocytopenic purpura [abstr]. Gastroenterology 1992;102:A889.
8. Hadziyanis Sj. Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci 1996; 41 (suppl 12);63S-74S.
9. Okabe M, Fukuda K, Arakawa K, Kikuchi M. Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 1997;96:22-4.
10. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 1995;92:2519-25.
11. Matsumori A, Matoba Y, Nishio R, Shioi T, Ono K, Sasayama S. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 1996;222:678-82.
12. Suarez A, Vallina E, Navascues CA, Rodrigues M, Otero L, Sottorrio NG, et al. Mixed type II cryoglobulinemia associated with chronic hepatitis C virus infection. Rev Clin Esp 1993;192:325-6.
13. Sansonno D, Cornacchiulo V, Iacobelli AR, Gatti P, Distasi M, Dammacco F. Hepatitis C virus infection and clonal B-cell expansion. Clin Exp Rheumatol 1996;14 (suppl 14):45-50.
14. Battegay M, Fikes J, Di Bescegli AM, Wentworth PA, Sette A, Celis E, et al. Patients with chronic hepatitis C have circulating T cells which recognise hepatitis C virus-encoded peptides to HLA-A2.1 molecules. J Virol 1995;69:2462-70.
15. Hoofnagel JH, Di Bisceglie AM. Drug therapy. The treatment of chronic viral hepatitis. N Eng J Med 1997;336:347-57.
16. Mansat E, Dreno B, Chiffoleau A, Litoux P. Cardiovascular manifestations associated with interferon-α-2A. Ann Med Interne Paris 1991;142:576-81.
17. Terwaga H, Hondo T, Amano H, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996;37:905-15.
18. Kadayifci A, Aytemir K, Arslan M, Aksoyek S, Sivri B, Kabacki G. Interferon-α does not cause significant cardiac dysfunction in patients with chronic active hepatitis. Liver 1997;17:99-102.
19. Ballardini P, Cicocnani I, Montanari E, Fabbri F, Ferrari R, Del-Noce A. Appearance of anti-DNA antibodies after treatment with interferon in a patient with chronic type C viral hepatitis. Eur Rev Sci Med Farmacol 1995;17:131-2.
20. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2. Eur J Endocrinol 1995;132:587-93.
21. Matsuda J, Saitoh N, Gotoh M, Gochi K, Tsukamoto M, Syoji S, et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995;90:1138-41.
22. Lopes E, Silva A, Sette Junior H, Guimaraes R, Ferraz M. Autoantibodies before, during and after administration of recombinant interferon-alpha for chronic viral hepatitis. Rev Inst Med Trop São Paulo 1995;37:455-60.
23. Floreani A, Chiaramonte M, Greggio NA, Fabris P, De Lazzari F, Naccarato R, Betterle C. Organ-specific autoimmunity and genetic predisposition in interferon treated HCV-related chronic hepatitis patients. Ital J Gastroenterol Hepatol 1998;30:71-6.
24. Amenomoro M, Mori T, Fukuda Y, Sugawa H, Nishida N, Furukawa M, et al. Incidence and characteristics of thyroid dysfunction following interferon therapy in patients with chronic hepatitis C. Intern Med 1998;37:246-52.
25. Piccolo G, Franciotta D, Versino M, Alfonsi E, Lombardi M, Poma G. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment [letter]. J Neurol Neurosurg Psychiatr 1996;60:348.
26. Siciliano R, Trovato BA, Semanara G, Giustolisi V, Malaguarnera M. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia A case report. Ann Ital Med Int 1995;10:193-4.
27. D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, Consoli G. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dis Sci 1995;40:2113-6.
28. Funk J, Langland T Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha therapy. Br J Dermatol 1991;125:463-5.
29. Teragawa H, Hondo T, Takahashi K, Wataneba H, Ohe H, Hattori N, et al. Sarcoidosis after interferon therapy for chronic active hepatitis C. Intern Med 1996;35:19-23.
30. Chazerain P, Meyer O, Ribard P, et al. Trois cas de polyarthite survenant au cours d un traitement par interferon-α recombinant. Rev Rhum Mal Ostéoartic 1992;59:303-9.
31. Kiely P, Bruckner F. Acute arthritis following interferon-α therapy [letter]. Br J Rheumatol 1994;33:502-3.
32. Pittau E, Bogliolo A, Tinti A, Mela Q, Ibba G, Salis G, Perpignano G. Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Clin Exp Rheumatol 1997;15:415-9.
33. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Krankzhoff M, et al. Lupus-like auto-immune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunopathol 1992;65:70-4.
34. Ronnblom LE, Aim GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon alpha treatment in a patient with a malignant carcinoid tumour. J Int Med 1990;227:207-10.
35. Schillings PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991;68:1536-7.
36. Machold CP, Smolen JS. Interferon gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol 1990;17:831-2.
37. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
38. Papo T, Piette JC, Lê Thi Huang D, Goudeau P. Interféron alpha et auto-immunité. Ann Med Interne 1993;5:357-66.
39. Selzer E, Wilfing A, Sexl V, Freissmuth M. Effects of type I-interferons on the human thyroid epithelial cells derived from normal and tumor tissue. Arch Pharmacol 1994;350:322-8.